摘要:
omicsonline.org 参考文章(35)
Daphne Ang, Rebecca O'Gara, Amy Schilling, Carol Beadling, Andrea Warrick, Megan L. Troxell, Christopher L. Corless, Novel Method for PIK3CA Mutation Analysis: Locked Nucleic Acid–PCR Sequencing The Journal of Molecular Diagnostics. ,vol. 15, pp. 312- 318 ,(2013) , 10.1016/J.JMOLDX.2012.12.005
Barbara L Parsons, Meagan B Myers, Personalized cancer treatment and the myth of KRAS wild-type colon tumors Discovery Medicine. ,vol. 15, pp. 259- 267 ,(2013)
Maria Vittoria Dieci, Valentina Guarneri, PIK3CA: a Target or a Marker in Breast Cancers Current Breast Cancer Reports. ,vol. 7, pp. 161- 169 ,(2015) , 10.1007/S12609-015-0184-1
Cristian Massacesi, Emmanuelle Tomaso, Nathalie Fretault, Samit Hirawat, Challenges in the clinical development of PI3K inhibitors Annals of the New York Academy of Sciences. ,vol. 1280, pp. 19- 23 ,(2013) , 10.1111/NYAS.12060
Paul Peter Rosen, Rosen's Breast Pathology ,(1997)
Eftychia Oikonomou, Evangelos Koustas, Maria Goulielmaki, Alexander Pintzas, BRAF vs RAS oncogenes: Are mutations of the same pathway equal? Differential signalling and therapeutic implications Oncotarget. ,vol. 5, pp. 11752- 11777 ,(2014) , 10.18632/ONCOTARGET.2555
Ezzeldin M. Ibrahim, Ghieth A. Kazkaz, Mubarak M. Al-Mansour, Meteb E. Al-Foheidi, The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis Breast Cancer Research and Treatment. ,vol. 152, pp. 463- 476 ,(2015) , 10.1007/S10549-015-3480-6
Sebastijan Hobor, Beth O. Van Emburgh, Emily Crowley, Sandra Misale, Federica Di Nicolantonio, Alberto Bardelli, TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells Clinical Cancer Research. ,vol. 20, pp. 6429- 6438 ,(2014) , 10.1158/1078-0432.CCR-14-0774
Filip Janku, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, David S. Hong, Vanda M. Stepanek, Siqing Fu, Sarina A. Piha-Paul, J. Jack Lee, Rajyalakshmi Luthra, Apostolia M. Tsimberidou, Razelle Kurzrock, PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials Cancer Research. ,vol. 73, pp. 276- 284 ,(2013) , 10.1158/0008-5472.CAN-12-1726
E. Razis, M. Bobos, V. Kotoula, A. G. Eleftheraki, H. P. Kalofonos, K. Pavlakis, P. Papakostas, G. Aravantinos, G. Rigakos, I. Efstratiou, K. Petraki, D. Bafaloukos, I. Kostopoulos, D. Pectasides, K. T. Kalogeras, D. Skarlos, G. Fountzilas, Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 128, pp. 447- 456 ,(2011) , 10.1007/S10549-011-1572-5